Why the study?
Can plasma methotrexate data identify patients at risk for serious toxicity during high dose therapy for solid tumors?
Can plasma methotrexate data identify patients at risk for serious toxicity during high dose therapy for solid tumors?
Pharmacokinetic monitoring of high-dose methotrexate can identify patients at risk for serious toxicity.
Answers are grounded in this paper and cite their sources.
Plasma MTX monitoring may flag toxicity risk in high-dose therapy; leaves open prospective validation before routine use.
In clinical studies performed during 111 infusions of high dose methotrexate (MTX) we have evolved a clinical and laboratory protocol which permits such therapy without prohibitive risk to the patient. The plasma MTX data obtained indicate that pharmacokinetic disposition is dose related during these infusions and that such data are useful in identifying patients at risk from serious toxicity.
No takes yet. Share an insight, caveat, or question.
Isacoff et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: